Loading...

Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species

Better understanding of roles of complement in pathology has fuelled an explosion of interest in complement-targeted therapeutics. The C5-blocking monoclonal antibody (mAb) eculizumab, the first of the new wave of complement blocking drugs, was FDA approved for treatment of Paroxysmal Nocturnal Hemo...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Front Immunol
Main Authors: Zelek, Wioleta M., Morgan, B. Paul
Format: Artigo
Sprog:Inglês
Udgivet: Frontiers Media S.A. 2020
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7793867/
https://ncbi.nlm.nih.gov/pubmed/33424866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.612402
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!